ANEXATE INJ 0.1MG/ML DIN 00874019
Health Canada record
| Active ingredient(s) | FLUMAZENIL 0.1 MG |
|---|---|
| Dosage form | Solution |
| Route | Intravenous |
| Schedule | ETHICAL |
| Class | Human |
| ATC | V03AB25 FLUMAZENIL |
| Original market date | 31-Dec-1991 |
| Current status date | 24-May-2012 |
| Source | Health Canada DPD |
Establishment licence of the holder
Hoffmann-La Roche Limited — licence 100006, currently licensed, last inspection rating C (2024-06-25).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing FLUMAZENIL
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02249561 | FLUMAZENIL INJECTION | SANDOZ CANADA INCORPORATED | Solution | FLUMAZENIL 0.1 MG | Marketed |
| 02266342 | FLUMAZENIL INJECTION, USP | FRESENIUS KABI CANADA LTD | Solution | FLUMAZENIL 0.1 MG | Marketed |
| 02431750 | JAMP-FLUMAZENIL | JAMP PHARMA CORPORATION | Solution | FLUMAZENIL 0.1 MG | Approved |
| 02388995 | FLUMAZENIL INJECTION SDZ | SANDOZ CANADA INCORPORATED | Solution | FLUMAZENIL 0.1 MG | Cancelled Pre Market |
| 02430169 | FLUMAZENIL INJECTION, USP | MYLAN PHARMACEUTICALS ULC | Solution | FLUMAZENIL 0.1 MG | Cancelled Pre Market |
International API supply for FLUMAZENIL
4 valid EDQM Certificates of Suitability from 4 holders. 4 active FDA Drug Master Files.
Request a quote for ANEXATE INJ 0.1MG/ML